Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ELANE | P08246 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11872189 | 0.84 | ELANE (0.45) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL9966585 | 0.82 | ELANE (0.49) | MAPTTDP1TSHRELANECYP1A2 | |
| SCHEMBL6043712 | 0.81 | MAPT (0.64) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL2365443 | 0.80 | TSHR (0.57) | TSHRELANE | |
| SCHEMBL6274253 | 0.78 | SMN1; SMN2 (0.59) | MAPTRAB9ASMN1; SMN2TSHRMAPK1 | |
| SCHEMBL11872179 | 0.78 | SMN1; SMN2 (0.46) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL15923823 | 0.77 | RAB9A (0.63) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL5632907 | 0.77 | RAB9A (0.77) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL16394878 | 0.76 | TSHR (0.52) | L3MBTL1TSHRELANE | |
| SCHEMBL20492122 | 0.75 | TDP1 (0.65) | MAPTRAB9ASMN1; SMN2TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140017797-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | De Staadt der Nederlanden, vert doorde minister van VWS (NL) | 2014-01-16 | — | — | US | disclosed |
| US-20140017797-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | De Staadt der Nederlanden, vert doorde minister van VWS (NL) | 2014-01-16 | — | — | US | disclosed |
| WO-2012081978-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | DE STAAT DER NEDERLANDEN, VERT. DOOR DE MINISTER VAN VWS (NL) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140017797-A1 | PROTEIN AFFINITY TAG AND USES THEREOF | PTMS, ALPG, TPX2 | MAPT 2203/4885RAB9A 4537/4885SMN1; SMN2 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.